Irish Biopharm Firm Gets Orphan Drug Designation From FDA


Apr 16, 2013

Silicon Republic

Dublin biopharmaceutical company Genable Technologies has been granted orphan drug designation from the Federal Drug Administration (FDA) in the US for its gene therapy product GT308 that it is developing to treat the eye disease retinitis pigmentosa.

The move from the FDA is being regarded by the company as a significant milestone, as it will provide Genable Technologies with seven years' market exclusivity once GT308 has secured regulatory approval. Read the full story here.
Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments